Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$IMMP: TIPRANKS, SCORE, UPGRADE TO 10 OUTPERFORM! ANALIST RATINGS: PT: $6.50 MODERATE BUY! LOW: @5.50, MED:@6.50, HI: $8.00 Jason McCarthy Maxim Group 5 Stars target $8.00 ranking Buy analystAction Reiterated date 6 days ago Last calification.
Cloudera (NYSE:CLDR) Given New $14.00 Price Target at Smith Barney Citigroup
MarketBeat
$CLRD: NEW CALIFICATION!
12/4/2020 Barclays Boost Price Target Equal Weight $12.00 ? $14.00 High
MarketBeat
Merrimack sold its oncology portfolio to Ipsen in April 2017 for $575M in upfront cash. MACK is eligible to receive up to an additional $450M triggered by the approval of additional indications for Onivyde in the U.S., a bullish prospect considering its current market cap of ~$77M.
https://seekingalpha.com/news/3640924-merrimack-pharma-jumps-42-on-bullish-timeline-for-potential-onivyde-milestone-payment
If you receive that amount of money, you will explode like $ KDAK, $ 46 in 3 days
$MACK:Merrimack sold its oncology portfolio to Ipsen in April 2017 for
$575M
in upfront cash. MACK is eligible to receive up to an additional
$450M
triggered by the approval of additional indications for Onivyde in the U.S., a bullish prospect considering its current market cap of ~
$77M
seekingalpha.com/news/36409...
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) was the recipient of some unusual options trading activity on Wednesday. Stock investors purchased 8,239 call options on the company. This is an increase of 5,115% compared to the average daily volume of 158 call options.
In related news, Director Noah G. Levy bought 69,087 shares of the stock in a transaction dated Tuesday, November 24th. The stock was purchased at an average cost of $3.65 per share, with a total value of $252,167.55. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 21.60% of the stock is currently owned by insiders.Several institutional investors and hedge funds have recently modified their holdings of MACK. Private Advisor Group LLC purchased a new stake in Merrimack Pharmaceuticals in the second quarter worth about $25,000. LVW Advisors LLC purchased a new stake in Merrimack Pharmaceuticals in the third quarter worth about $80,000. Bronte Capital Management Pty Ltd. purchased a new stake in Merrimack Pharmaceuticals in the third quarter worth about $2,052,000. Nantahala Capital Management LLC lifted its stake in Merrimack Pharmaceuticals by 0.6% in the third quarter. Nantahala Capital Management LLC now owns 751,943 shares of the biopharmaceutical company’s stock worth $3,008,000 after acquiring an additional 4,308 shares during the period. Finally, Western Standard LLC lifted its stake in Merrimack Pharmaceuticals by 3.1% in the second quarter. Western Standard LLC now owns 869,354 shares of the biopharmaceutical company’s stock worth $2,895,000 after acquiring an additional 26,441 shares during the period. 45.83% of the stock is owned by hedge funds and other institutional investors.
Shares of MACK traded up $2.41 during trading hours on Wednesday, reaching $6.49. 77,082,195 shares of the company traded hands, compared to its average volume of 370,655. Merrimack Pharmaceuticals has a 12-month low of $1.49 and a 12-month high of $7.10. The stock’s fifty day moving average price is $3.83 and its 200 day moving average price is $3.66.
https://www.americanbankingnews.com/2020/12/02/merrimack-pharmaceuticals-sees-unusually-high-options-volume-nasdaqmack.html
Morgan Stanley raised its stake in Marathon Patent Group by 333,397.4% during the 3rd quarter. Morgan Stanley now owns 126,729 shares of the business services provider’s stock valued at $248,000 after purchasing an additional 126,691 shares during the period.
Separately, HC Wainwright started coverage on Marathon Patent Group in a research report on Monday. They set a “buy” rating and a $7.50 price objective for the company.11/23/2020
https://www.americanbankingnews.com/2020/11/23/marathon-patent-group-nasdaqmara-stock-price-up-45-1.html
TIPRANKS SCORE 8 OUTPERFORM!
Copa Holdings Q3 EPS $(2.86) Misses $(2.74) Estimate, Sales $32.38M Miss $39.02M Estimate
4:32 pm ET November 18, 2020 (Benzinga) Print
Copa Holdings (NYSE:CPA) reported quarterly losses of $(2.86) per share which missed the analyst consensus estimate of $(2.74) by 4.38 percent. This is a 216.73 percent decrease over earnings of $2.45 per share from the same period last year. The company reported quarterly sales of $32.38 million which missed the analyst consensus estimate of $39.02 million by 17.01 percent. This is a 95.43 percent decrease over sales of $708.21 million the same period last year.
$73 PRICE, CRAZY!
9/17/2020 Stifel Nicolaus Boost Price Target Buy $11.00 ? $14.00 Hight
MarketBeat!
$CS Upgrade to Outperform, PT:$13.00 16/11/2020 TDA.
UPDATE: SmileDirectClub narrows Q3 loss, sees 'broader acceptance' of teledentistry
Today 4:33 PM ET (MarketWatch)
By Claudia Assis
mileDirectClub Inc. shares rose 2% in the extended session Monday after the teledentistry company reported a narrower-than-expected quarterly loss and sales that were above Wall Street's expectations.
SmileDirectClub (SDC) said it lost $43 million, or 11 cents a share, in the third quarter, compared with losses of $388 million, or 89 cents a share, in the year-ago quarter.
Revenue rose to $169 million from $157 million a year ago.
Analysts polled by FactSet had expected the company to report a loss of 17 cents a share on sales of $146 million.
SmileDirectClub, which makes lower-cost teeth-straightening retainers, said it remains focused "on providing the best club-member experience, while driving controlled and profitable growth."
"The company expects to continue to see favorable industry dynamics with broader acceptance of telehealth and specifically teledentistry," and has no "real competitor," it said in a statement that did not specifically address the effects of the pandemic.
After-hours gains moderated after the report. Shares of SmileDirectClub have gained 14% this year, compared with gains around 12% for the S&P 500 index.
-Claudia Assis; 415-439-6400; AskNewswires@dowjones.com
(END) Dow Jones Newswires
November 16, 2020 16:33 ET (21:33 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
https://research.tdameritrade.com/grid/public/markets/news/story.asp?docKey=1-SN20201116009936-3HQOMTACG0E695BFANJ6QIB1S2&CID=1-SN20201116009936-MAP
(NASDAQ:OBSV) shares gapped up prior to trading on Monday . The stock had previously closed at $2.07, but opened at $2.35. ObsEva shares last traded at $2.23, with a volume of 1,519 shares traded.
A number of brokerages have commented on OBSV. HC Wainwright reduced their price target on ObsEva from $36.00 to $23.00 and set a “buy” rating for the company in a research report on Monday, October 5th. JPMorgan Chase & Co. cut ObsEva from a “neutral” rating to an “underweight” rating in a research report on Monday, November 9th. Wedbush restated a “buy” rating and issued a $30.00 price target on shares of ObsEva in a research report on Friday, August 14th. Finally, Zacks Investment Research cut ObsEva from a “buy” rating to a “hold” rating in a research report on Saturday, November 7th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the stock. ObsEva presently has a consensus rating of “Hold” and an average price target of $12.61.
The firm has a market cap of $99.36 million, a PE ratio of -0.83 and a beta of 0.95. The firm has a fifty day simple moving average of $2.27 and a two-hundred day simple moving average of $3.23. The company has a debt-to-equity ratio of 1.06, a quick ratio of 2.52 and a current ratio of 2.52.
ObsEva (NASDAQ:OBSV) last released its quarterly earnings results on Thursday, November 5th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.15). Equities analysts forecast that ObsEva SA will post -1.57 EPS for the current fiscal year.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Morgan Stanley grew its holdings in ObsEva by 1,023.1% during the 3rd quarter. Morgan Stanley now owns 477,467 shares of the company’s stock valued at $1,184,000 after buying an additional 434,953 shares in the last quarter. State Street Corp purchased a new position in ObsEva during the 3rd quarter valued at approximately $124,000. Acadian Asset Management LLC purchased a new position in ObsEva during the 3rd quarter valued at approximately $414,000. GSA Capital Partners LLP bought a new stake in shares of ObsEva in the 3rd quarter valued at approximately $38,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of ObsEva by 32.1% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 255,995 shares of the company’s stock valued at $635,000 after purchasing an additional 62,192 shares during the last quarter. Institutional investors and hedge funds own 48.54% of the company’s stock.
https://www.americanbankingnews.com/2020/11/16/obseva-nasdaqobsv-shares-gap-up-to-2-07.html
INSTITUTIONAL OWNERSHIP CHANGES (13F FILINGS) FOR OBSEVA (NASDAQ:OBSV)
Institutional Ownership Percentage: 48.54%
11/13/2020 Morgan Stanley 477,467 $1.18M 0.0% +1,023.1% 0.995%
11/12/2020 Arrowstreet Capital Limited Partnership 84,444 $0.21M 0.0% -28.8% 0.176%
11/10/2020 State Street Corp 49,994 $0.12M 0.0% N/A 0.104%
11/9/2020 Acadian Asset Management LLC 166,998 $0.41M 0.0% N/A 0.348%
11/6/2020 GSA Capital Partners LLP 15,265 $38K 0.0% N/A 0.032%
11/6/2020 Zurcher Kantonalbank Zurich Cantonalbank 255,995 $0.64M 0.0% +32.1% 0.533%
11/5/2020 Cutter & CO Brokerage Inc. 10,550 $26K 0.0% -67.8% 0.022%
10/20/2020 Wedbush Securities Inc. 179,037 $0.44M 0.0% +19.5% 0.373%
9/15/2020 Two Sigma Advisers LP 20,400 $0.12M 0.0% -30.8% 0.043%
8/14/2020 Point72 Asset Management L.P. 275,000 $1.62M 0.0% -44.7% 0.566%
8/14/2020 Logos Global Management LP 1,165,000 $6.86M 1.4% N/A 2.399%
8/12/2020 Goldman Sachs Group Inc. 11,499 $68K 0.0% -81.1% 0.024%
8/12/2020 California Public Employees Retirement System 68,100 $0.40M 0.0% N/A 0.140%
8/11/2020 Aigen Investment Management LP 35,977 $0.21M 0.0% N/A 0.074%
8/10/2020 Cutter & CO Brokerage Inc. 32,750 $0.19M 0.1% N/A 0.067%
8/7/2020 Virtu Financial LLC 47,334 $0.28M 0.0% N/A 0.097%
TIPRANks Based on 3 analysts offering 12 month price targets for ObsEva SA in the last 3 months. The average price target is $24.50 with a high forecast of $26.00 and a low forecast of $23.00. The average price target represents a 1061.14% increase from the last price of $2.11.
tipranks.com/stocks/obsv/fo...
Zomedica Pharm Is Maintained at Buy by HC Wainwright & Co. From $0.50 to $0.30
6:42 am ET November 16, 2020 (Dow Jones) Print
Ratings actions from Benzinga: https://www.benzinga.com/stock/ZOM/ratings
(END) Dow Jones Newswires
November 16, 2020 06:42 ET (11:42 GMT)
As Gordon Gekko says, if you need a friend, get a dog!
Why Zomedica Pharmaceuticals Is Surging Today
By Sarah Smith, InvestorPlace Web Content Producer Nov 13, 2020, 3:03 pm EST
Animal lovers, unite! Zomedica Pharmaceuticals (NYSEMKT:ZOM), an under-the-radar play on the pet care space, is having an impressive time in the stock market today. In fact, one big catalyst has ZOM stock up more than 20% today.
A close-up shot of a smiling veterinarian and a grey fluffy dog.
Source: Shutterstock
So what exactly is Zomedica Pharmaceuticals? And what is that big catalyst? Starting with the first question, Zomedica Pharmaceuticals says that its goal is to improve the quality of veterinarian care by helping more veterinarians be successful. To do this, Zomedica works to provide veterinarian solutions that help with diagnostics.
Essentially, the easier it is for vets to figure out what is wrong with an animal, the easier it is to begin treatment.
With that in mind, Zomedica Pharmaceuticals shared exciting news on Friday. The company said that it expects to begin commercialization of its Truforma point-of-care diagnostics platform by March 2021. What does that mean? Well, Truforma uses bulk acoustic wave (BAW) technology to help detect thyroid and adrenal diseases in dogs and cats. Importantly, Zomedica says that this BAW tech helps improve accuracy, precision and timeliness. Instead of waiting for results, the Truforma platform can give patients insight during an initial appointment.
There are a few other things for investors to note here. To start, Zomedica believes that it is the first company to use BAW tech in this way. Along with this, the company has 70 issued or pending patents on Truforma, giving it a competitive edge in the pet care market. As investors consider the commercialization catalyst, they can also have some confidence that Zomedica will retain its dominance for some time.
ZOM Stock and the Coronavirus Pandemic
Although the commercialization story is clearly an exciting one, there is another big catalyst lurking beneath the surface. Yes, that catalyst is the novel coronavirus pandemic.
As Americans spent more time than ever before at home, they increasingly turned to furry friends for comfort. Shelters emptied out. Dogs and cats flocked to new homes. And most importantly, spending on pet health and care products increased. In fact, unlike in previous economic crises, Americans spent more than before on their four-legged companions.
What does this mean for Zomedica Pharmaceuticals and ZOM stock? Well, there are now more households in America with dogs and cats. These households in turn are also spending more than before on taking care of their pets. All together, this means pet owners and vets will likely jump at the chance to provide better and more accurate diagnostics. For Zomedica, this should translate to steady demand for its Truforma point-of-care platform and any following diagnostic solutions.
On the date of publication, Sarah Smith did not have (either directly or indirectly) any positions in the securities mentioned in this article.
Sarah Smith is a Web Content Producer for InvestorPlace.com.
https://investorplace.com/2020/11/zom-stock-news-why-zomedica-pharmaceuticals-is-surging-today/
$ JPM bought, that means he knows something about TRUFORMA or that there is a possible acquisition.
Hard to tell, but you don't buy a small cap. for no reason.
JPMorgan Chase & Co. Buy 285,800 Shares $29K 11/12/2020
MarketBeat.
BlackRock Inc. boosted its stake in T2 Biosystems by 34.6% in the third quarter. BlackRock Inc. now owns 2,203,844 shares of the medical equipment provider’s stock worth $2,998,000 after buying an additional 566,115 shares in the last quarter. Geode Capital Management LLC increased its stake in T2 Biosystems by 100.5% in the first quarter. Geode Capital Management LLC now owns 759,200 shares of the medical equipment provider’s stock valued at $493,000 after purchasing an additional 380,459 shares in the last quarter. Hussman Strategic Advisors Inc. bought a new stake in T2 Biosystems in the third quarter valued at approximately $350,000. Bridgeway Capital Management Inc. boosted its holdings in shares of T2 Biosystems by 161.6% in the second quarter. Bridgeway Capital Management Inc. now owns 404,700 shares of the medical equipment provider’s stock valued at $514,000 after buying an additional 250,000 shares during the period. Finally, California Public Employees Retirement System acquired a new position in shares of T2 Biosystems in the third quarter valued at approximately $299,000. 10.06% of the stock is owned by institutional investors.
A number of other research firms have also commented on TTOO. ValuEngine raised shares of T2 Biosystems from a “hold” rating to a “buy” rating in a research report on Wednesday, September 2nd. Zacks Investment Research lowered shares of T2 Biosystems from a “buy” rating to a “hold” rating in a research report on Tuesday, October 13th. Canaccord Genuity lowered their price target on shares of T2 Biosystems from $4.00 to $3.50 and set a “buy” rating on the stock in a research report on Thursday. Alliance Global Partners raised their price target on shares of T2 Biosystems from $1.65 to $2.60 and gave the stock a “buy” rating in a research report on Thursday. Finally, BTIG Research assumed coverage on shares of T2 Biosystems in a research report on Wednesday, October 7th. They set a “buy” rating and a $2.50 price target on the stock. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $2.62.
https://www.americanbankingnews.com/2020/11/09/t2-biosystems-inc-nasdaqttoo-forecasted-to-post-fy2020-earnings-of-0-38-per-share.html
T2 Biosystems price target raised to $2.60 from $1.65 at Alliance Global Alliance Global Partners analyst Ben Haynor raised the firm's price target on T2 Biosystems to $2.60 from $1.65 and reiterates a Buy rating on the shares following the company's Q3 results.
Read more at:
https://thefly.com/n.php?id=3189807
Maintained at Outperform by SVB Leerink. Upgrade PT from $3.00 to $4.00
4:17 am ET November 5, 2020 (Dow Jones) Print
Ratings actions from Benzinga: https://www.benzinga.com/stock/TTOO/ratings
(END) Dow Jones Newswires
November 05, 2020 04:17 ET (09:17 GMT)
T2 Biosystems (TTOO - Research Report) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.31 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 20%. A quarter ago, it was expected that this diagnostics company would post a loss of $0.18 per share when it actually produced a loss of $0.09, delivering a surprise of 50%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.
T2 Biosystems, which belongs to the Zacks Medical - Instruments industry, posted revenues of $5.25 million for the quarter ended September 2020, surpassing the Zacks Consensus Estimate by 32.45%. This compares to year-ago revenues of $1.68 million. The company has topped consensus revenue estimates two times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
T2 Biosystems shares have added about 15.4% since the beginning of the year versus the S&P 500's gain of 4.3%.
What's Next for T2 Biosystems?
While T2 Biosystems has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for T2 Biosystems was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.09 on $10.15 million in revenues for the coming quarter and -$0.45 on $19.21 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Instruments is currently in the bottom 30% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
https://www.zacks.com/stock/news/1096760/t2-biosystems-ttoo-reports-q3-loss-tops-revenue-estimates?art_rec=quote-stock_overview-zacks_news-ID01-txt-1096760
$SUP: 3 Wall Street analysts have issued ratings and price targets for Superior Industries International in the last 12 months. Their average twelve-month price target is $4.00, predicting that the stock has a possible upside of 109.42%. The high price target for SUP is $7.00 and the low price target for SUP is $1.00. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of "Hold."
7/10/2020 Barrington Research Reiterated Rating Buy $7.00 High
3/19/2020 B. Riley Downgrade Buy ? Neutral $5.00 ? $1.00 High
1/9/2020 Benchmark Initiated Coverage Hold Low
9/24/2019 BWS Financial Set Price Target Hold $6.00 Low
Current Short Volume: 532,300 shares
Previous Short Volume: 525,300 shares
Change Vs. Previous Month: +1.33%
Dollar Volume Sold Short: $686,667.00
Short Interest Ratio / Days to Cover: 3.0
Last Record Date: October, 15 2020 Very low!
----------------------------------------------------------
Ticker: SUP
CUSIP Number: 868168105
Top investors of Superior Industries International stock
Who bought or sold Superior Industries International this quarter?
Dimensional Fund Advisors 1.6M $2.7M -22% Jun 2020
D.C. Capital Advisors 1.2M $2.0M 0% Jun 2020
Vanguard Group 804k $1.4M 0% Jun 2020
Millennium Management 730k $1.2M -10% Jun 2020
Renaissance Technologies 558k $948k 34% Jun 2020
Plaisance Capital 527k $897k 44% Jun 2020
GAMCO Asset Management 444k $755k -34% Jun 2020
Goldman Sachs Group 400k $680k 100% Jun 2020
D. E. Shaw & Co 281k $478k 12% Jun 2020
Jacobs Levy Equity Management 197k $334k 100% Jun 2020
Sunrise Partners Limited Partnership 193k $329k 0% Jun 2020
Geode Capital Management 192k $325k 0% Jun 2020
Gabelli Funds 191k $325k -24% Jun 2020
Royce & Associates 151k $256k -25% Jun 2020
Invesco 148k $251k -13% Jun 2020
Two Sigma Advisers 142k $242k -1% Jun 2020
South Dakota Investment Council 140k $238k 0% Jun 2020
Acadian Asset Management 112k $191k -16% Jun 2020
Wells Fargo & Company 91k $146k -30% Jun 2020
Arrowstreet Capital, Limited Partnership 84k $143k -20% Jun 2020
Northern Trust 76k $0 -4% Jun 2020
Bridgeway Capital Management 75k $127k 0% Jun 2020
Pinnacle Holdings 71k $120k -1% Jun 2020
Morgan Stanley 71k $0 -74% Jun 2020
Winton Capital 67k $84k -19% Sep 2020
NJ State Employees Deferred Compensation Plan 62k $78k 0% Sep 2020
Integrated Investment Consultants 40k $50k 0% Sep 2020
Susquehanna International 40k $68k -43% Jun 2020
UBS Group 38k $65k 4% Jun 2020
Royal Bank of Canada 37k $64k 8% Jun 2020
Tudor Investment Corporation 33k $56k 0% Jun 2020
O'shaughnessy Asset Management 32k $54k -16% Jun 2020
Citadel Advisors 26k $45k 149% Jun 2020
Advisory Services Network 26k $45k 0% Jun 2020
State Street Corporation 26k $44k 0% Jun 2020
Eidelman Virant Capital 20k $34k 100% Jun 2020
Assenagon Asset Management 20k $24k -85% Sep 2020
Qube Research & Technologies 19k $33k 100% Jun 2020
Investors Research Corp 19k $24k 0% Sep 2020
Bank of New York Mellon 16k $0 -1% Jun 2020
Bank of America Corporation 15k $27k -8% Jun 2020
Bank Of Montreal 8.0k $13k 0% Jun 2020
Group One Trading 2.9k $5.0k 383% Jun 2020
Center for Financial Planning 2.0k $3.0k 0% Jun 2020
Benjamin F. Edwards & Company 2.0k $3.0k 100% Jun 2020
PanAgora Asset Management 1.7k $3.0k 0% Jun 2020
Gradient Investments 915.00 $1.0k 0% Sep 2020
Flagship Harbor Advisors 800.00 $1.0k 0% Sep 2020
Bnp Paribas Arbitrage, Snc 150.00 $187.995000 0% Sep 2020
Glenmede Trust Company 41.00 $0 -72% Jun 2020
Meeder Asset Management 12.00 $0 0% Jun 2020
Jpmorgan Chase & Co 5.00 $0 -100% Jun 2020
2 Wall Street analysts have issued ratings and price targets for Gevo in the last 12 months. Their average twelve-month price target is $4.00, predicting that the stock has a possible upside of 244.83%. The high price target for GEVO is $5.00 and the low price target for GEVO is $3.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
8/31/2020 HC Wainwright Reiterated Rating Buy $5.00 Medium
3/19/2020 Noble Financial Reiterated Rating Buy $3.00 High
---------------------------------------
ZACKS: 2 STRONG BUY GREEN. PT:$3.58
Zomedica Pharmaceuticals Corp (NYSE: ZOM) shares climbed 42.9% to $0.10 on Monday after tumbling 29% on Friday. Zomedica recently announced plans to develop gastrointestinal testing panel for TRUFORMA.September 22, 2020 (Benzinga)
ZACKS: 3 HOLD PT:$5.00
---------------------------
JAGUAR HEALTH (NASDAQ:JAGX) PRICE TARGET AND CONSENSUS RATING
1 Wall Street analysts have issued ratings and price targets for Jaguar Health in the last 12 months. Their average twelve-month price target is $3.00, predicting that the stock has a possible upside of 678.21%. The high price target for JAGX is $3.00 and the low price target for JAGX is $3.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
HC Wainwright Reiterated Rating Buy $10.00 ? $3.00 Low
LADENBURG THALM/SH SH Initiated Coverage Buy $5.00 High
MarketBeat
Oragenics Inc. to Present at the H.C. Wainwright 22nd Annual Global Virtual Investment Conference
Business Wire Business Wire•September 11, 2020
Oragenics, Inc. (NYSE American: OGEN), a biopharmaceutical company dedicated to the development and commercialization of a vaccine candidate to combat the novel coronavirus pandemic (commonly referred to as COVID-19) today announces that Alan Joslyn, Ph.D., President and Chief Executive Officer, is scheduled to present at the H.C. Wainwright 22nd Annual Global Investment Conference (the "Conference"). The Conference is to be held virtually on September 14–16, 2020, and Dr. Joslyn is scheduled to present on Wednesday, September 16, 2020 at 11:00 AM ET.
A live webcast of Dr. Joslyn’s presentation will be available through H.C. Wainwright’s virtual conference portal, located here, and the presentation will be archived on the Oragenics website at https://www.oragenics.com.
In addition, Dr. Joslyn will be available for virtual one-on-one meetings from September 14–16, 2020. To schedule a meeting with Dr. Joslyn, please contact the Conference coordinator at meetings@hcwco.com.
About Oragenics, Inc.
Oragenics, Inc. is focused on the creation of the Terra CoV-2 vaccine candidate to combat the novel coronavirus pandemic and the further development of effective treatments for novel antibiotics against infectious disease. Oragenics is dedicated to the development and commercialization of a vaccine candidate providing specific immunity from novel coronavirus. The Terra CoV-2 immunization leverages coronavirus spike protein research conducted by the National Institute of Health. In addition, Oragenics also has an exclusive worldwide channel collaboration with ILH Holdings, Inc. (n/k/a Eleszto Genetika, Inc.) relating to the development of novel lantibiotics.
For more information about Oragenics, please visit www.oragenics.com.
Safe Harbor Statement
Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect management’s current views with respect to future events and performance. These forward-looking statements are based on management’s beliefs and assumptions and information currently available. The words "believe," "expect," "anticipate," "intend," "estimate," "project" and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to, the following: the Company’s ability to advance the development of TerraCoV2 under the timelines and in accord with the milestones it projects; the Company’s ability to obtain funding for the development of Noachis Terra’s TerraCoV2 vaccine, whether through its own cash on hand, a grant from BARDA, or another alternative source; the regulatory application process, research and development stages, and future clinical data and analysis relating to TerraCoV2, including any decisions by regulatory authorities, such as the FDA and investigational review boards, whether favorable or unfavorable; the Company’s ability to obtain, maintain and enforce necessary patent and other intellectual property protection; the nature of competition and development relating to COVID-19 immunization and therapeutic treatments; other potential adverse impacts due to the global COVID-19 pandemic, such as delays in regulatory review, interruptions to manufacturers and supply chains, adverse impacts on healthcare systems and disruption of the global economy; and general economic and market conditions risks, as well as other uncertainties described in our filings with the U.S. Securities and Exchange Commission. Oragenics assumes no responsibility to update any forward-looking statements contained in this press release or with respect to the matters described herein.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200911005120/en/
Contacts
Oragenics:
Michael Sullivan
Chief Financial Officer
813-286-7900
msullivan@oragenics.com
Investors:
John Marco
Managing Director
CORE IR
516-222-2560
johnm@coreir.com
Media:
Jules Abraham
CORE IR
917-885-7378
julesa@coreir.com
https://finance.yahoo.com/news/oragenics-inc-present-h-c-113000999.html
OGEN: SARS-CoV-2 Vaccine to Enter the Clinic in Early 2021…
Zacks Small Cap Research Zacks Small Cap Research•September 3, 2020
By David Bautz, PhD
NYSE:OGEN
READ THE FULL OGEN RESEARCH REPORT
Business Update
Developing Vaccine Against SARS-CoV-2
In May 2020, Oragenics, Inc. (NYSE:OGEN) announced the acquisition of Noachis Terra Inc., which is developing TerraCoV2, a vaccine candidate against SARS-CoV-2 (the virus that causes COVID-19) that is licensed from the National Institute of Allergy and Infectious Diseases (NIAID). We anticipate the vaccine entering the clinic in early 2021.
The vaccine candidate is targeted against the prefusion spike protein found on the surface of SARS-CoV-2. The spike (S) protein is found on all coronaviruses and is used for receptor recognition and entry into target cells (Li, 2016). The S protein is produced as a single amino acid chain before being cleaved into two non-covalently bound subunits, S1 and S2. These subunits then trimerize to form a large prefusion spike protein. The complex undergoes a conformational change in order to bind to cell surface receptors that allows for cell entry (Wrapp et al., 2020).
Generating antibodies directed against the spike protein is a preferred strategy for vaccine development, however generating a recombinant spike protein that retains the prefusion conformation is difficult, as the complex can spontaneously change to the membrane fusion form. This is important because antibodies directed against the prefusion complex can bind the S protein as it exists on the surface of the virus, while antibodies directed against the membrane fusion form are not effective at neutralizing the virus. Multiple studies in this field have advanced our knowledge on producing stable, prefusion spike proteins, as shown by research into vaccines against HIV (Sanders et al., 2002) and MERS (Pallesen et al., 2017). The vaccine acquired by Oragenics utilizes a prefusion form of the S protein for SARS-CoV-2 for vaccination. In addition, it is produced in a mammalian expression system (Chinese Hamster Ovary [CHO] cells), which allows for the proper glycosylation pattern, another important aspect to ensuring an immunogenic antigen. The following figure gives an example of antigenic sites on the RSV F protein, and how some of those antigenic sites on the prefusion form of the molecule are not present on the postfusion form, thus exemplifying why producing a stable, prefusion form of the S protein is critical for vaccine development (Flynn et al., 2016).
In addition to the intellectual property acquired with Noachis Terra, Oragenics will be working with Noachis Terra’s Consulting Director of Research and Development, Dr. David Zarley, on the development of TerraCoV2. Dr. Zarley was involved in the creation of Flumist® along with vaccine candidates against parainfluenza and rotavirus during his career.
Oragenics recently signed a process development and drug substance manufacturing agreement with Avid Bioservices, Inc., in which Avid will provide analytical method development, process development, and drug substance manufacturing services for TerraCoV2. All of these activities are designed to support the goal of getting TerraCoV2 vaccine candidate into clinical testing in early 2021.
Robust Antibody Response to SARS-CoV-2 S-2P
A preclinical study examined the immune response to various doses of the stabilized prefusion spike protein (SARS-CoV-2 S-2P) in different strains of mice1 (Corbett et al., 2020). The following figure shows that immunization with S-2P elicits antibody titers that are similar to those incited by mRNA-1273, the lead SARS-CoV-2 vaccine candidate being developed by Moderna Inc. (MRNA). S-2P was immunized with Sigma Adjuvant System (SAS) as an adjuvant, which is an oil-in-water emulsion that is an alternative to Freund’s adjuvant. In addition, the similar levels of both IgG1 and IgG2a/c antibodies is indicative of a balanced Th1/Th2 response.
Immunization with S-2P also elicits robust neutralizing antibody (Nab) titers in BALB/c mice. The following table shows the levels of Nab from three separate serum pools following immunization with S-2P and SAS. These values were similar to the Nab levels induced by mRNA-1273.
New Board Member Adds Expertise in Vaccine Development
In May 2020, Oragenics announced it has increased the size of its Board of Directors and added Ms. Kim Murphy to the board. Ms. Murphy has been involved in all aspects of vaccine development from previous experience with GlaxoSmithKline (GSK). At GSK, she led the global influenza vaccine and pandemic preparedness business and also managed a 2,000-employee team responsible for vaccine development, sales, manufacturing, and distribution. Prior to GSK, she held various commercialization and marketing roles within Novartis Vaccines and Diagnostics Inc. and Merck. Her knowledge of vaccine development and experience will be vital to Oragenics as it embarks on developing TerraCoV2.
Financial Update
On August 14, 2020, Oragenics filed form 10-Q with financial results for the second quarter of 2020. As expected, the company did not report any revenues during the second quarter of 2020. R&D expenses were $11.5 million for the second quarter of 2020, compared to $3.9 million for the second quarter of 2019. The increase was primarily due to the acquisition of Noachis Terra, Inc. and an increase in costs associated with the TerraCoV2. G&A expenses for the second quarter of 2020 were $0.8 million, compared to $1.0 million for the second quarter of 2019. The decrease was primarily due to decreased filing fees and registration costs, travel and entertainment costs, consulting fees, and stock-based compensation.
Oragenics exited the second quarter of 2020 with approximately $9.6 million in cash and cash equivalents. Subsequent to the end of the quarter, the company generated gross proceeds of $5.1 million from the exercise of approximately 5.5 million warrants. We estimate the company has sufficient capital to fund operations into the second quarter of 2021. As of August 7, 2020, Oragenics had approximately 61.0 million shares of common stock outstanding and when factoring in stock options and warrants a fully diluted share count of approximately 89.6 million.
Valuation
At this point we have removed AG013 from our valuation model and value the company based on TerraCov2, OG716, the cash on hand, and potential cash from warrant exercises. For modeling purposes, we anticipate the Phase 1 trial of TerraCoV2 initiating in early 2021 with approval in late 2022. For OG716, we model for clinical trials to initiate in 2021, an NDA filing in 2025, and approval in 2026. We believe if successful, TerraCoV2 could attain $1 billion in revenues in a relatively short amount of time given the urgency to vaccinate the world’s population. We also model for OG716 to reach $275 million in peak sales. Our current valuation for Oragenics is $3.00.
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks provides and Zacks receives quarterly payments totaling a maximum fee of $40,000 annually for these services. Full Disclaimer HERE.
________________________
1. Kizzmekia Corbett, et al., “SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness,” bioRxiv June 2020[doi: https://doi.org/10.1101/2020.06.11.145920]
https://finance.yahoo.com/news/ogen-sars-cov-2-vaccine-134700204.html
I understand perfectly, but the $ CS cannot manipulate $ TVIX.
It is not allowed by the SEC.
$TVIX: It is being manipulated by the $ CS
It had 142 Million shares before 1/10. It was left with 14.2 million, more than 2.5 million shares overturned during the low. They bought on the downside and removed an average of 7 million shares from the market to raise the price. Friday ended with 9.1 million shares, today is already 9.5 million shares.
All this without issuing an 8k notifying shareholders
Stop using $ AAPL as a smokescreen! Apple is a monster company, with more money than many banks, that is the true assets of a company, its liquidity.
Correction to the downside in a short time! RSI(14)69.72
https://stockcharts.com/h-sc/ui?s=TWLO&p=D&yr=0&mn=3&dy=0&id=p61829176931
$MTSL: WOW! VOLCANO?? $2.82 + 57%
https://stockcharts.com/h-sc/ui?s=MTSL&p=D&yr=0&mn=3&dy=0&id=p61829176931
Micron Technology (MU) PT Set at $68.00 by Goldman Sachs Group
https://www.fairfieldcurrent.com/2018/07/18/micron-technology-mu-pt-set-at-68-00-by-goldman-sachs-group.html
Turbo Global partnerships
November 30, 2017
Share Tweet Comments (0)
Turbo Global Partners, a Carson City-based marketing consulting services company, has signed a Sole-source Memorandum of Agreement with DEX Imaging, Inc., an independent provider of office technology based in Tampa, Fla.
Turbo also announced the initial launch of the Marketing Program for Millisecond Technologies Corp. to bring the MSTC technology to the global market
https://www.nnbw.com/news/news-briefs/turbo-global-partnerships/
Turbo Global Partners signs new joint venture
October 16, 2017
Share Tweet Comments (0)
Turbo Global Partners, a marketing consulting firm headquartered in Carson City, has partnered with Millisecond Technologies Corp., to form a joint venture marketing company.
Millisecond is a New York-based company that has developed a patented pasteurization technology that improves production efficiency and extends the shelf-life of milk.Turbo will own a 60 percent stake in the partnership with Millisecond owning a 40 percent stake.
The joint venture will result in an initial marketing budget of $3.3 million for Turbo, commencing in 2018, to market Millisecond’s technology to dairies around the United States and United Kingdom
http://www.nnbw.com/news/turbo-global-partners-signs-new-marketing-partnership/
(TRBO) RMI Reading Nearing Potential Peak
Drilling into the technicals for Turbo Global Partners Inc. (TRBO), we have noticed that the Relative Momentum Indicator, or RMI, has been trending higher over the past week. Traders will be actively monitoring current levels as the shares potentially close in on overbought territory.
Similar to RSI, the RMI indicator moves in the range of 0 to 100; and the same as with RSI, the relative Momentum Index’s values above 70 and below 30 are considered as an indication of overbought and oversold conditions. Since RMI readings above 50 are considered as bullish and RMI readings below 50 are considered as bearish, some traders may choose to generate signals on the crossovers of the RMI and 50 center line: sell when RMI decline below 50 and buy when RMI advances above 50.
In taking a deeper dive into the numbers. presently, Turbo Global Partners Inc. (TRBO) has a 14-day ATR of 0.00. The Average True Range is widely used metric that helps gauge the volatility of a particular stock. The ATR is not used to measure price direction, just to measure volatility. The ATR is an indicator developed by J. Welles Wilder. Wilder has developed multiple indicators that are still quite popular in today’s investing landscape. The general interpretation of the ATR is the higher the ATR value, the higher the volatility.
The Williams Percent Range or Williams %R is another technical indicator worth checking out. Turbo Global Partners Inc. (TRBO) currently has a 14 day Williams %R of -50.00. The Williams %R fluctuates between 0 and -100 measuring whether a security is overbought or oversold. The Williams %R is similar to the Stochastic Oscillator except it is plotted upside-down. Levels above -20 may indicate the stock may be considered is overbought. If the indicator travels under -80, this may signal that the stock is oversold. Chart analysts may also use the indicator to project possible price reversals and to define trends.
The Average Directional Index or ADX is technical analysis indicator used to discern if a market is trending or not trending. The ADX alone measures trend strength but not direction. Using the ADX with the Plus Directional Indicator (+DI) and Minus Directional Indicator (-DI) may help determine the direction of the trend as well as the overall momentum. Many traders will use the ADX alongside other indicators in order to help spot proper trading entry/exit points. Currently, the 14-day ADX for Turbo Global Partners Inc. (TRBO) is 21.31. Generally speaking, an ADX value from 0-25 would indicate an absent or weak trend. A value of 25-50 would indicate a strong trend. A value of 50-75 would signal a very strong trend, and a value of 75-100 would indicate an extremely strong trend.
Traders may be leaning on technical stock analysis to help with investing decisions. Turbo Global Partners Inc. (TRBO) currently has a 14-day Commodity Channel Index (CCI) of 150.85. Despite the name, CCI can be used on other investment tools such as stocks. The CCI was designed to typically stay within the reading of -100 to +100. Traders may use the indicator to determine stock trends or to identify overbought/oversold conditions. A CCI reading above +100 would imply that the stock is overbought and possibly ready for a correction. On the other hand, a reading of -100 would imply that the stock is oversold and possibly set for a rally.
Traders are paying renewed attention to shares of Turbo Global Partners Inc. (TRBO). The current 14-day RSI is presently sitting at 52.02, the 7-day is 56.25, and the 3-day is 56.89. The RSI, or Relative Strength Index is a popular oscillating indicator among traders and investors. The RSI operates in a range-bound area with values between 0 and 100. When the RSI line moves up, the stock may be experiencing strength. The opposite is the case when the RSI line is heading lower. Different time periods may be used when using the RSI indicator. The RSI may be more volatile using a shorter period of time. Many traders keep an eye on the 30 and 70 marks on the RSI scale. A move above 70 is widely considered to show the stock as overbought, and a move below 30 would indicate that the stock may be oversold. Traders may use these levels to help identify stock price reversals.
https://buckeyebusinessreview.com/2017/10/13/turbo-global-partners-inc-trbo-rmi-reading-nearing-potential-peak/